Chinese expert consensus on the clinical application of thrombopoietin receptor agonist in the perioperative period of liver cancer (2025 edition)

Thrombocytopenia is one of the common complications in patients with liver cancer, which has an important impact on the whole‑course treatment management of liver cancer patients. In recent years, thrombopoietin receptor agonists have been used to treat thrombocy-topenia associated with chronic liver disease. The Editorial Board of Chinese Journal of Digestive Surgery have organized domestic experts in related fields to follow the principles of evidence‑based medicine, combine with clinical practice experience, conduct in‑depth demonstration, and carry out multiple discussions and revisions, so as to formulate the Chinese expert consensus on the clinical application of thrombopoietin receptor agonist in the perioperative period of liver cancer (2025 edition)". This consensus has formed 8 recommended opinions, aiming to guide the standardized application of thrombopoietin receptor agonists in the treatment of thrombocytopenia during the perioperative period of liver cancer.